Combination therapy for large liver cancer before surgery
Part of Cancer clinical trials.
This trial tests a combination of treatments—chemotherapy given directly into the liver, two immunotherapy drugs, and a targeted therapy—for people with liver cancer that is too large or complex for immediate surgery. The goal is to shrink the tumor enough to make surgery possible later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have liver cancer (hepatocellular carcinoma) that has not spread to other parts of the body, except for a few spots that are allowed.
- The tumor must be large (at least 5 cm) and there can be no more than 3 tumors.
- You must not be able to have surgery to remove the tumor right now, according to your doctors.
- You must not have received any previous medicine for liver cancer (oral or by IV).
- Your liver must be working fairly well (Child-Pugh score of 7 or less), and you must be in good general health (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a drug that cuts off blood supply to the tumor) given after surgery or ablation for liver cancer. The goal is to lower the chance of cancer coming back. The treatment is given as an infusion and may help patients with certain high-risk features.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.